NUTEX HEALTH REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
Nutex Health reported Q3 2026 revenue of $217.6 million, down 18.7% YoY, with net income attributable to the company of $40.2 million ($5.71 diluted EPS) versus $55.4 million ($7.76) a year ago. For the first nine months, net income rose 159% to $152.9 million ($21.50 diluted EPS) on revenue of $644.9 million, down 10.9% YoY, boosted by a $52.3 million non-cash contract-services expense reduction tied to the amended HaloMD agreement and lower CMS administrative fee. Cash generation remained solid: nine-month operating cash flow was $188.1 million, and the balance sheet shows $249.9 million of cash against $34.2 million of long-term debt.
Key figures
- Eps
- 5.71
- Revenue
- 644850000
- Revenue Yoy
- -10.9% (nine months)
- Cash
- 249911000
- Q3 revenue
- 217613000
- Visits yoy
- +18.1%
- Total assets
- 1032376000
- Q3 net income
- 40229000
- Q3 diluted eps
- 5.71
- Q3 revenue yoy
- -18.7%
- Q3 total visits
- 54622
- Adjusted ebitda 9m
- 211426000
- Adjusted ebitda q3
- 63877000
- Long term debt net
- 34200000
- Noncash eps impact
- 4.83
- Nine month net income
- 152878000
- Nine month diluted eps
- 21.5
- Operating cash flow 9m
- 188065000
- Adjusted ebitda q3 prior
- 98530000
- Q3 prior year net income
- 55435000
- New hospitals expected q4
- 2
- Nine month net income yoy
- +159%
- Noncash change in estimate benefit
- 52300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.